Filing Flows › Usana Health Sciences (USNA) › Guidance & outlook
Usana Health Sciences (USNA) guidance and outlook
Usana Health Sciences (USNA) lowered its guidance on Nov 3, 2026: Revenue $900M for FY2026; EBITDA $77.0M for FY2026; Revenue $740M for FY2026; EPS −$0.90 for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $900M | new |
| EBITDA | FY2026 | $77.0M | new |
| Revenue | FY2026 | $740M | lowered |
| Revenue | FY2026 | $130M | new |
| EPS | FY2026 | −$0.90 | lowered |
| EPS | FY2026 | −$1.00 | reaffirmed |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Usana Health Sciences' latest quarter
Usana Health Sciences, Q2 2026: revenue $223M (-5% year over year), operating margin -9.0%, net loss $28.0M, operating cash flow $23.3M. The chart follows the revenue to costs, profit and cash.
Questions
Did Usana Health Sciences raise or lower its guidance?
Usana Health Sciences (USNA) lowered its guidance on Nov 3, 2026: Revenue $900M for FY2026; EBITDA $77.0M for FY2026; Revenue $740M for FY2026; EPS −$0.90 for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.